Aurinia Pharmaceuticals Inc. AUPH R2K
Healthcare · Biotechnology · Canada
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
READ MORE ›$15.33
+95.54% 1Y
Market & Price
Market Cap
$1.97B
Current Price
$15.33
High / Low (52W)
$16.42 / $7.47
Beta
1.45
Valuation
Stock P/E
7.10
Industry PE
23.65
Forward P/E
13.71
PEG Ratio
-
Book Value
$4.34
Price to Book
3.53
P/S
6.61
EV/EBITDA
10.81
Dividend Yield
-
Profitability & Returns
ROCE
18.01%
ROE
64.98%
ROA
13.66%
Profit Margin
99.97%
Op Margin
53.31%
EPS (Latest Qtr)
$0.25
EPS (TTM)
$2.16
Balance Sheet & Liquidity
Debt/Equity
0.12
Quick Ratio
4.95
Current Ratio
5.55
Debt
$68.64M
Total Assets
$751.59M
Current Assets
$491.97M
Working Capital
$398.24M
Ownership
Promoter Holding
7.53%
Chg in Prom Hold
0.09%
FII / Inst Holding
59.43%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$1.66B
Total Revenue (TTM)
$298.30M
EBITDA
$153.71M
Free Cash Flow
$124.63M
Operating Cash Flow
$166.92M
Shares Outstanding
128.60M
Gross Margin
78.27%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
28.30%
Profit 5Y
121.83%
Revenue (YoY)
24.40%
Earnings (YoY)
56.30%
PROS
- Strong return on equity of 65.0%.
- Excellent profit margin of 100.0%.
- Compounding revenue at 28.3% over 5 years.
- Profit CAGR of 121.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AUPH Aurinia Pharmaceuticals Inc. R2K | 15.33 | 7.10 | $1.97B | - | 18.01% | 64.98% | 28.30% | 121.83% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.00K | 29.00K | 230.00K | 29.00K | 30.00K | 29.00K | 29.00K | 50.03M | 914.00K | 6.62M | 14.67M | 23.40M | 21.62M | 28.19M | 55.78M | 28.43M | 34.41M | 41.49M | 54.52M | 45.09M | 50.30M | 57.19M | - | - | 62.47M | 70.01M | 73.47M | 77.11M | 77.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.57M | 7.12M | 8.18M | 8.80M | 6.50M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.89M | 62.89M | 65.29M | 68.31M | 71.20M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.51M | 42.70M | 35.55M | 35.08M | 29.78M |
| Operating Income | -14.89M | -17.14M | -24.07M | -34.84M | -27.06M | -26.86M | -42.31M | -8.05M | -50.54M | -47.13M | -50.35M | -32.70M | -37.88M | -35.99M | -9.50M | -28.10M | -29.58M | -16.17M | -16.26M | -29.67M | -13.25M | -1.51M | - | - | 23.38M | 20.20M | 29.75M | 33.24M | 41.42M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.27M | 28.14M | 37.93M | 41.60M | 49.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07M | 1.12M | 1.10M | 1.05M | 1.01M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.35M | 22.16M | 31.96M | 35.69M | 43.92M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 643.00K | 411.00K | -175.10M | 9.57M |
| Net Income | -14.10M | -16.38M | -23.45M | -34.46M | -25.93M | -26.54M | -42.13M | -8.07M | -50.38M | -47.01M | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.88M | -10.75M | 722.00K | - | - | 23.34M | 21.51M | 31.55M | 210.79M | 34.35M |
| Diluted EPS | - | - | - | - | -0.23 | -0.24 | -0.34 | -0.06 | -0.40 | -0.37 | -0.39 | -0.25 | -0.27 | -0.25 | -0.06 | -0.18 | -0.18 | -0.08 | -0.09 | -0.19 | -0.07 | 0.01 | - | - | 0.16 | 0.16 | 0.23 | 1.53 | 0.25 |
| R&D Expense | - | - | - | - | 13.84M | 11.08M | 12.24M | - | 9.83M | 10.09M | 20.07M | - | 12.62M | 11.53M | 10.97M | - | 13.16M | 12.65M | 13.61M | - | 5.55M | 4.08M | 3.05M | - | 5.74M | 7.43M | 8.44M | - | 7.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 463.00K | 318.00K | 50.12M | - | 134.03M | 175.51M | 235.13M | 283.06M |
| Cost of Revenue | - | - | - | - | 5.66M | 14.15M | 28.25M | 32.66M |
| Gross Profit | - | - | - | - | 128.37M | 161.37M | 206.88M | 250.39M |
| Operating Expenses | - | - | - | - | 239.84M | 253.06M | 188.47M | 143.83M |
| Operating Income | -55.24M | -90.94M | -104.29M | - | -111.47M | -91.69M | 18.42M | 106.56M |
| EBITDA | - | - | - | - | -103.65M | -63.05M | 31.73M | 137.94M |
| Interest Expense | - | - | - | - | 0 | 2.77M | 4.83M | 4.33M |
| Pretax Income | - | - | - | - | -106.35M | -77.47M | 7.45M | 114.16M |
| Tax Provision | - | - | - | - | 1.83M | 551.00K | 1.70M | -173.04M |
| Net Income | -53.08M | -88.39M | -102.68M | - | -108.18M | -78.02M | 5.75M | 287.20M |
| Diluted EPS | - | -0.95 | -0.87 | - | -0.76 | -0.54 | 0.04 | 2.07 |
| R&D Expense | 41.38M | 52.87M | 50.33M | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M |
Compounded Sales Growth
| 5 Years: | 28.30% |
| 1 Year: | 24.40% |
Compounded Profit Growth
| 5 Years: | 121.83% |
| 1 Year: | 56.30% |
Stock Price Performance
| 1 Year: | +95.54% |
| 6 Months: | -5.84% |
| 3 Months: | +8.19% |
| 1 Month: | +0.33% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 324.30M | 463.66M | - | 470.86M | 548.06M | 550.64M | 751.59M |
| Current Assets | - | - | - | - | - | 442.54M | 424.80M | 446.60M | 491.97M |
| Cash & Equivalents | - | - | 306.02M | 272.35M | - | 94.17M | 48.88M | 83.43M | 80.21M |
| Inventory | - | - | - | - | - | 24.75M | 39.70M | 39.23M | 45.69M |
| Receivables | - | - | - | - | - | 13.48M | 24.09M | 36.54M | 41.45M |
| Total Liabilities | - | - | 25.70M | 55.91M | - | 65.42M | 170.11M | 173.17M | 170.26M |
| Current Liabilities | - | - | 11.29M | 32.00M | - | 46.11M | 77.19M | 97.76M | 93.72M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 8.09M | 97.61M | 79.37M | 74.81M |
| Total Equity | 177.92M | 135.72M | 298.60M | 407.75M | - | 405.44M | 377.95M | 377.48M | 581.33M |
| Shares Outstanding | - | - | - | - | - | 142.27M | 143.83M | 140.88M | 132.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.61M | -63.59M | -69.86M | - | -79.53M | -33.46M | 44.39M | 135.66M |
| Investing Cash Flow | -65.00K | 7.78M | -158.19M | - | -60.63M | -6.71M | 39.26M | -32.77M |
| Financing Cash Flow | 4.01M | 243.85M | 194.38M | - | 2.43M | -5.13M | -49.09M | -106.11M |
| Capital Expenditure | - | - | - | - | -292.00K | -718.00K | -281.00K | -252.00K |
| Free Cash Flow | - | - | - | - | -79.82M | -34.18M | 44.11M | 135.41M |
| Net Change in Cash | - | - | - | - | -137.73M | -45.30M | 34.56M | -3.22M |
| Share Buybacks | - | - | - | - | 0 | 0 | 40.24M | 98.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating Margin % | -11,930.9% | -28,598.4% | -208.1% | - | -83.2% | -52.2% | 7.8% | 37.6% |
| Net Margin % | -11,464.1% | -27,794.0% | -204.9% | - | -80.7% | -44.5% | 2.4% | 101.5% |
| ROE % | -39.1% | -29.6% | -25.2% | - | -26.7% | -20.6% | 1.5% | 49.4% |
| ROCE % | - | -29.1% | -24.2% | - | -26.2% | -19.5% | 4.1% | 16.2% |
Shareholding Pattern
Insiders
7.53%
Institutions
59.43%
Public Float
64.27%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tang Capital Management, LLC | 9.51% | 12.23M | $187.48M |
| 2 | Blackrock Inc. | 6.10% | 7.85M | $120.27M |
| 3 | NEA Management Company, LLC | 3.09% | 3.97M | $60.86M |
| 4 | Two Sigma Investments, LP | 2.67% | 3.43M | $52.56M |
| 5 | Arrowstreet Capital, Limited Partnership | 2.55% | 3.28M | $50.35M |
| 6 | State Street Corporation | 1.97% | 2.53M | $38.74M |
| 7 | Morgan Stanley | 1.74% | 2.23M | $34.22M |
| 8 | Marshall Wace LLP | 1.46% | 1.87M | $28.74M |
| 9 | Renaissance Technologies, LLC | 1.29% | 1.66M | $25.51M |
| 10 | Shaw D.E. & Co., Inc. | 1.22% | 1.57M | $24.11M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AUPH
No recent headlines available.